查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016958

心室辅助装置市场：2026-2032年全球市场预测（依装置类型、类别、流量等级、适应症及最终用户划分）

Ventricular Assist Device Market by Device Type, Category, Flow Class, Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心室辅助装置市场价值将达到 15 亿美元，到 2026 年将成长至 16.3 亿美元，到 2032 年将达到 27.2 亿美元，复合年增长率为 8.78%。

主要市场统计数据
基准年 2025 15亿美元
预计年份：2026年 16.3亿美元
预测年份 2032 27.2亿美元
复合年增长率 (%) 8.78%

针对心室辅助装置环境的综合框架，重点在于临床发展、技术整合以及医疗保健系统的需求。

过去十年间，心室辅助装置已从最初的小众救命疗法发展成为进行进行性心臟衰竭治疗路径中不可或缺的选择，这主要得益于其耐用性、生物相容性和植入技术的进步。现代装置设计优先考虑降低血栓形成风险、小型化和提高能源效率，从而扩大了其在老年患者和併发症疾病患者中的应用范围。同时，先进的外科手术方法和经皮支持策略降低了手术全期风险，使得心室辅助装置在三级医疗机构和专科医疗机构中得到更广泛的应用。

临床、工程和商业领域的整合变革如何推动机械循环支援领域的新路径和基于价值的方法。

多项因素的融合正在重塑心室辅助装置的研发、评估和应用。首先，包括轴流式和离心式平台在内的连续流设计工程技术的进步，提高了血流动力学效率和耐久性，从而影响手术适应症的选择和长期管理。其次，数位遥测和远端监测功能的集成，使得对装置性能和患者状态进行主动管理成为可能，缩短了门诊患者和植入团队之间的反馈週期。

2025 年美国关税变化将如何促使整个设备生态系统的供应链在地化、采购流程重组和商业策略调整？

2025年实施的关税调整增加了心室辅助装置整个供应链的复杂性，影响到组件、完整系统以及相关一次性用品。这些政策变化促使医院采购团队和医疗设备製造商更严格地审查采购流程，并重新评估筹资策略、供应商多元化和库存管理。为此，一些製造商正在加快关键组件的在地化生产，并利用契约製造生产来降低贸易相关价格波动带来的风险。

本研究旨在阐明流程架构、设备类型、临床适应症、产品设计和护理环境如何相互交织，形成差异化的临床和商业性路径。

连续流系统和脉动平台在血流架构上的差异持续影响临床实务。连续流装置（尤其是轴流和离心式装置）因其可靠性和小型化而备受青睐，而脉动技术则占据着特定的细分市场，因为生理性脉动在临床上更受青睐。将装置类型分为左心室、右心室和双心室系统，凸显了治疗目标如何驱动技术设计。左心室辅助仍然是慢性病治疗中最常用的模式，而右心室和双心室解决方案在急性心臟衰竭和复杂的围手术全期病例中发挥着至关重要的作用。

法规结构、支付方趋势以及临床引入方面的区域差异，塑造了世界各地不同的商业化和证据生成策略。

美洲地区拥有完善的三级医疗网络、高度集中的专业植入中心，以及强调可靠临床证据和上市后监测的监管流程。这些条件有利于先进植入技术和复杂护理方案的推广应用。相较之下，欧洲、中东和非洲（EMEA）地区的医疗环境高度异质化，报销机制、国家卫生部门流程和医院采购模式差异显着，因此需要灵活的商业化策略和针对特定区域的临床合作。同时，亚太地区某些市场的医疗基础设施正在快速发展，而其他市场则拥有高度先进、卓越的医疗中心，因此该地区的两大重点在于：成本效益高的解决方案和尖端创新技术的应用。

竞争动态和伙伴关係策略强调平台创新、服务整合以及在整个设备生态系统中基于证据的差异化。

行业相关人员采取了多种策略来实现产品差异化。一些公司优先考虑对医疗设备进行渐进式改进，以提高生物相容性和电池效率；而另一些公司则专注于平台主导倡议，整合远端监控和预测分析。医疗设备开发商与学术机构之间的策略合作正在加速转化研究和临床检验，并加快迭代改进週期。此外，服务网络的垂直整合和内部技术支援团队的扩充，正成为企业与医院建立长期合作关係并维持植入式医疗设备高运转率的关键差异化因素。

製造商和供应商在医疗设备治疗领域加强供应韧性、证据产生和价值主导经营模式的具体策略重点。

首先，我们将优先投资于上市后资料收集和远端监测基础设施，以验证设备在真实临床环境中的性能，并促进其早期临床应用。将循证研究与支付方的要求和临床医生的优先事项相结合，将简化报销谈判流程，并促进更广泛的应用。其次，我们将实现关键零件供应商多元化，并尽可能探索本地製造伙伴关係，以降低贸易中断和前置作业时间波动带来的风险，从而增强供应链的韧性。第三，我们将开发包含医疗设备硬体、保固服务和可预测服务合约的捆绑式商业方案，以简化采购流程，并降低医院系统的营运风险。

采用严谨的混合方法研究方法，结合一手临床访谈、二手证据和相关人员检验，以获得可靠的研究结果。

本研究途径融合了定性和定量方法，旨在全面了解临床实践、技术趋势和商业性动态。主要资料收集包括对临床医生、临床工程师、采购经理和监管专家进行结构化访谈，以获取关于设备性能、服务期望和推广障碍的实际观点。次要文献整合则利用同行评审的临床研究、指南、监管公告和技术白皮书，为主要研究结果提供背景资讯并检验临床结论。

简明扼要地整合了技术进步、不断发展的临床实践和策略挑战，以实现机械循环支援的永续发展。

总而言之，心室辅助装置（VAD）领域正处于一个转折点，技术进步、不断演变的临床适应症和不断变化的商业性环境相互交织，既带来了新的机会，也带来了新的挑战。设备在血流技术、小型化和数位化整合方面的改进，使得更多患者能够受益，并能实现更精细的治疗路径。同时，与定价相关的供应链压力以及监管和报销体系的区域差异，要求企业制定灵活的商业性和营运策略。因此，那些能够将卓越的技术、强大的实证医学能力、稳健的供应链网络以及完善的临床医生和患者支持计划相结合的机构，才能最终取得成功。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：心室辅助装置市场：依装置类型划分

  • 双心室型
  • 左边
  • 正确的

第九章：心室辅助装置市场：依类别划分

  • 种植类型
  • 体外型

第十章 依流量类型分類的心室辅助装置市场

  • 连续流
    • 轴流式
    • 圆神流
  • 脉衝流

第十一章 心室辅助装置市场：依适应症划分

  • 弥合復苏差距
  • 弥合移植差距
  • 最终治疗

第十二章 心室辅助装置市场：依最终使用者划分

  • 门诊手术中心
  • 医院

第十三章 心室辅助装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 心室辅助装置市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 心室辅助装置市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国心室辅助装置市场

第十七章 中国心室辅助装置市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Abiomed
  • Berlin Heart GmbH
  • BiVACOR Inc.
  • Calon Cardio-Technology Ltd.
  • CARMAT SA
  • CH Biomedical Inc.
  • CorWave SAS
  • Evaheart, Inc.
  • Jarvik Heart, Inc.
  • LivaNova PLC
  • Medtronic plc
  • ReliantHeart Inc.
  • SynCardia Systems, LLC
  • Terumo Corporation
Product Code: MRR-034B5003038B

The Ventricular Assist Device Market was valued at USD 1.50 billion in 2025 and is projected to grow to USD 1.63 billion in 2026, with a CAGR of 8.78%, reaching USD 2.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.50 billion
Estimated Year [2026] USD 1.63 billion
Forecast Year [2032] USD 2.72 billion
CAGR (%) 8.78%

A comprehensive framing of the ventricular assist device environment highlighting clinical evolution, technology convergence, and health-system imperatives

Over the past decade, ventricular assist devices have transitioned from niche salvage therapies to integral options within advanced heart failure care pathways, driven by improvements in durability, biocompatibility, and implantation techniques. Contemporary device architectures emphasize reduced thrombogenicity, smaller form factors, and energy efficiency, which together have expanded candidacy among older and more comorbid patients. Simultaneously, refined surgical approaches and percutaneous-adjunct strategies have lowered perioperative risk, thereby enabling wider institutional adoption across tertiary and specialized centers.

Moreover, shifting clinical paradigms have blurred traditional boundaries between temporary and long-term mechanical circulatory support, prompting clinicians to consider device therapy earlier in the disease course for select patient cohorts. Payers and health systems are increasingly focused on value-based outcomes and readmission reduction, which elevates the importance of longitudinal device performance and comprehensive peri-implant care programs. As a result, manufacturers, clinicians, and hospitals are coalescing around evidence-generation and real-world data initiatives to quantify quality-of-life improvements and long-term survival benefits.

In parallel, regulatory frameworks continue to evolve to balance timely patient access with robust post-market surveillance, encouraging iterative device enhancements while maintaining patient safety. Taken together, these dynamics have created a complex but fertile environment for innovation, partnership, and strategic differentiation across the ecosystem supporting ventricular assist device therapy.

How convergent clinical, engineering, and commercial transformations are driving new adoption pathways and value-based approaches in mechanical circulatory support

Several convergent shifts are redefining how ventricular assist devices are developed, evaluated, and deployed. First, engineering advances in continuous flow designs, including axial and centrifugal platforms, have enhanced hemodynamic efficiency and durability, which in turn influence surgical selection and long-term management. Second, integration of digital telemetry and remote monitoring capabilities is enabling proactive management of device performance and patient status, thus shortening feedback loops between outpatient clinicians and implant teams.

Concurrently, clinical evidence is expanding indications beyond classic bridge-to-transplant scenarios toward bridge-to-recovery and destination therapy for select populations, prompting multidisciplinary teams to reassess candidacy criteria. The rise of patient-centered outcomes has shifted evaluation metrics to include functional status and quality of life, not solely survival, which affects reimbursement conversations and clinical adoption. Furthermore, manufacturing and supply chain strategies are evolving as companies pursue vertical integration, production scalability, and regulatory harmonization across jurisdictions to reduce time to market for iterative device updates.

Finally, strategic collaborations among device manufacturers, academic centers, and health systems are accelerating translational research and real-world evidence generation. These partnerships are fostering adaptive clinical trial designs and registries that better capture long-term device performance and complications, thereby informing iterative improvements in patient selection, perioperative protocols, and post-implant care.

Assessing how 2025 United States tariff changes are prompting supply chain localization, procurement realignment, and commercial strategy adjustments across the device ecosystem

Tariff adjustments implemented in 2025 have introduced complexity across the ventricular assist device supply chain, affecting components, finished systems, and ancillary disposables. These policy changes have increased procurement scrutiny among hospital purchasing teams and device manufacturers, prompting reassessments of sourcing strategies, supplier diversification, and inventory management. In response, some manufacturers have accelerated localization of critical component production and engaged contract manufacturers to mitigate exposure to trade-related price volatility.

Healthcare providers have reacted by enhancing procurement governance and exploring longer-term supply agreements to provide price stability and continuity of care. At the same time, smaller suppliers and niche component vendors have experienced differential impacts, leading to potential consolidation as organizations seek scale to absorb tariff-related cost pressures. Importantly, clinical teams are monitoring any indirect effects on device availability and service parts, because even modest disruptions can influence scheduled implant programs and post-implant support.

Policy uncertainty has also elevated the role of total cost of care analyses in procurement decisions, with hospital systems demanding greater transparency around landed costs, warranty terms, and service network reliability. As a result, manufacturers that proactively adapt their commercial models to offer bundled service agreements, improved lead-time assurances, and localized support are positioned to maintain competitive advantage under the revised tariff environment.

Decoding how flow architecture, device type, clinical indication, product design, and care setting intersect to create differentiated clinical and commercial pathways

Flow architecture distinctions between continuous flow systems and pulsatile platforms continue to shape clinical practice, with continuous flow devices-particularly axial and centrifugal configurations-favored for their reliability and smaller profiles, whereas pulsatile technologies retain a defined niche where physiologic pulsatility is clinically prioritized. Device type segmentation into left, right, and biventricular systems underscores how therapeutic intent drives technological design; left ventricular support remains the most commonly deployed modality for chronic support, while right and biventricular solutions play critical roles in acute decompensation and complex perioperative cases.

Indication-based differentiation across bridge-to-recovery, bridge-to-transplant, and destination therapy informs not only clinical decision-making but also programmatic design within health systems, as each indication demands distinct pre-implant evaluation, follow-up care pathways, and psychosocial support models. Product-level choices between external and implantable systems further interact with patient lifestyle considerations, infection risk management, and long-term device maintenance strategies. Finally, end-user segmentation that includes ambulatory surgical centers alongside hospitals highlights evolving care-delivery models, with ambulatory settings increasingly managing select perioperative workflows while hospitals retain responsibility for complex implants and long-term management.

Together, these segmentation axes intersect to create nuanced adoption patterns and service needs, suggesting that manufacturers and providers who align product development, clinical support, and training programs to these differentiated requirements will be better positioned to address clinician preferences and patient expectations.

Regional distinctions in regulatory frameworks, payer dynamics, and clinical adoption that shape commercialization and evidence-generation strategies across global territories

The Americas region features advanced tertiary care networks, a high concentration of specialized implant centers, and regulatory pathways that emphasize robust clinical evidence and post-market surveillance; these conditions support the adoption of advanced implantable technologies and complex care programs. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape where reimbursement mechanisms, national health authority processes, and hospital procurement models vary significantly, driving the need for flexible commercialization strategies and region-specific clinical engagement. Meanwhile, Asia-Pacific encompasses rapidly developing health infrastructure in certain markets alongside highly advanced centers of excellence in others, creating a dual focus on cost-effective solutions and cutting-edge innovation adoption.

Across these regions, local clinical practice patterns, surgeon experience, and the density of specialized heart failure programs influence how quickly new device architectures are integrated into treatment algorithms. Furthermore, regulatory harmonization efforts and regional initiatives to strengthen post-market data collection are beginning to reduce barriers to multi-jurisdictional evidence generation, although implementation timelines remain uneven. As a result, companies pursuing global expansion must tailor clinical education, service networks, and reimbursement strategies to accommodate diverse payer expectations and healthcare delivery models while leveraging regional centers of excellence to accelerate clinician adoption and build robust real-world evidence.

Competitive dynamics and partnership strategies that emphasize platform innovation, service integration, and evidence-led differentiation across the device ecosystem

Industry participants have pursued divergent strategies to differentiate offerings: some prioritize incremental device refinements to improve hemocompatibility and battery efficiency, while others emphasize platform initiatives that integrate remote monitoring and predictive analytics. Strategic partnerships between device developers and academic institutions have accelerated translational research and clinical validation, enabling faster cycles of iterative improvement. In addition, vertical integration of service networks and the expansion of in-house technical support teams have emerged as critical differentiators for companies seeking to secure long-term hospital relationships and ensure high uptime for implanted devices.

Mergers and acquisitions remain a pathway for acquiring complementary technologies, bolstering service capabilities, and expanding geographic reach, particularly where companies seek to plug gaps in product lines or augment post-market surveillance infrastructure. At the same time, newer entrants and specialized component suppliers are challenging incumbents by offering niche innovations in areas such as driveline infection mitigation, sensor integration, and hemodynamic optimization algorithms. Collectively, these competitive dynamics prioritize not only device performance but also the quality of clinical training, clarity of warranty and service commitments, and the depth of evidence supporting long-term patient outcomes.

Actionable strategic priorities for manufacturers and providers to reinforce supply resilience, evidence generation, and value-driven commercial models in device therapy

First, prioritize investment in post-market data collection and remote monitoring infrastructure to demonstrate real-world device performance and drive earlier clinical acceptance. Aligning evidence-generation efforts with payer requirements and clinician priorities will facilitate reimbursement discussions and support broader adoption. Second, strengthen supply chain resilience by diversifying suppliers of critical components and by exploring localized manufacturing partnerships where feasible to reduce exposure to trade-related disruption and lead-time variability. Third, develop bundled commercial offerings that combine device hardware, warranty coverage, and predictable service agreements to simplify procurement and reduce operational risk for hospital systems.

Moreover, expand clinician education programs that incorporate simulation, proctorship, and multidisciplinary care-team training to minimize perioperative complications and optimize patient selection. Leverage regional centers of excellence to accelerate peer-to-peer knowledge transfer and to generate high-quality real-world evidence. Finally, adopt a patient-centered product development mindset that emphasizes quality of life, ease of use, and long-term care coordination, because these factors increasingly drive device preference among clinicians and patients alike. By implementing these recommendations in concert, leaders can strengthen competitive positioning while improving clinical outcomes and operational reliability.

A rigorous mixed-methods research approach integrating primary clinical interviews, secondary evidence synthesis, and stakeholder validation for reliable insights

The research approach integrates qualitative and quantitative methods to produce a comprehensive view of clinical practice, technology trends, and commercial dynamics. Primary data collection involves structured interviews with clinicians, clinical engineers, procurement leaders, and regulatory specialists to capture frontline perspectives on device performance, service expectations, and adoption barriers. Secondary literature synthesis draws on peer-reviewed clinical studies, guideline statements, regulatory communications, and technical white papers to contextualize primary findings and to verify clinical assertions.

In addition, structured stakeholder validation sessions were used to reconcile divergent viewpoints, test hypotheses emerging from the analysis, and refine recommendations. Where appropriate, device technical specifications, bench-test reports, and post-market surveillance summaries were cross-referenced to corroborate claims about device architecture and clinical application. Throughout, methodological rigor was maintained by applying transparent inclusion criteria for sources, documenting interview protocols, and employing iterative triangulation to enhance reliability. This mixed-methods design ensures that the insights are both clinically grounded and operationally relevant for decision-makers.

A concise synthesis linking technological advancement, clinical practice evolution, and strategic imperatives for sustainable progress in mechanical circulatory support

In synthesis, the ventricular assist device field is at an inflection point where engineering advances, evolving clinical indications, and shifting commercial realities converge to create new opportunities and challenges. Device improvements in flow technology, miniaturization, and digital integration are enabling broader patient access and more refined care pathways, while tariff-related supply-chain pressures and regional variability in regulation and reimbursement require adaptive commercial and operational strategies. Consequently, successful organizations will be those that combine technical excellence with robust evidence-generation, resilient supply networks, and comprehensive clinician and patient support programs.

Looking ahead, coordinated efforts among manufacturers, clinical leaders, and health systems to prioritize real-world data collection, streamline procurement models, and enhance training will be essential to translate technological promise into sustained clinical benefit. By focusing on these integrated priorities, stakeholders can improve patient outcomes, reduce system-level risks, and position device therapy as a durable, patient-centered option within advanced heart failure care paradigms.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ventricular Assist Device Market, by Device Type

  • 8.1. Biventricular
  • 8.2. Left
  • 8.3. Right

9. Ventricular Assist Device Market, by Category

  • 9.1. Implantable
  • 9.2. External

10. Ventricular Assist Device Market, by Flow Class

  • 10.1. Continuous Flow
    • 10.1.1. Axial Flow
    • 10.1.2. Centrifugal Flow
  • 10.2. Pulsatile Flow

11. Ventricular Assist Device Market, by Indication

  • 11.1. Bridge To Recovery
  • 11.2. Bridge To Transplant
  • 11.3. Destination Therapy

12. Ventricular Assist Device Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals

13. Ventricular Assist Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ventricular Assist Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ventricular Assist Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ventricular Assist Device Market

17. China Ventricular Assist Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Abiomed
  • 18.7. Berlin Heart GmbH
  • 18.8. BiVACOR Inc.
  • 18.9. Calon Cardio-Technology Ltd.
  • 18.10. CARMAT SA
  • 18.11. CH Biomedical Inc.
  • 18.12. CorWave SAS
  • 18.13. Evaheart, Inc.
  • 18.14. Jarvik Heart, Inc.
  • 18.15. LivaNova PLC
  • 18.16. Medtronic plc
  • 18.17. ReliantHeart Inc.
  • 18.18. SynCardia Systems, LLC
  • 18.19. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VENTRICULAR ASSIST DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVENTRICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVENTRICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVENTRICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LEFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LEFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LEFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RIGHT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RIGHT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY IMPLANTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY IMPLANTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY IMPLANTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 120. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 141. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 146. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 148. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)